Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral MOA-728 for Opioid-Induced Bowel Dysfunction
NCT00366431Phase 2Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in opioid-induced bowel dysfunction (OIBD) comparing MOA-728 with Placebo (2 arms). Primary endpoint: Change from baseline in the number of bowel movements per week. Started Aug 2006; status: completed.
02
Drugs
methylnaltrexone
03
Conditions
opioid-induced bowel dysfunction (OIBD)
Beyond the preview
Go deeper on NCT00366431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00366431.